Delphi study producing the content of the National Risk Medicines Classification has been launched

The Delphi study to produce the data content of the national risk medicines classification was launched at the end of August. The working group selected the potential risk medicines included in the survey based on international classifications and literature on high-risk medicines.  In the first round of the survey, 51 experts commented on the medicines included the survey. The experts also had the opportunity to propose new medicines for evaluation in the survey.

The second Delphi round, which will be launched at the beginning of October, reassesses the medicines that did not reach a clear consensus in the first round. The second survey assesses the risks associated with the included medicines, either related to the pharmaceutical substance or the medication process. The third survey will focus on assessing and commenting on the risk management descriptions of the medicines. 

The content of the risk medicines classification will be formulated by the end of 2022. The final classification will be published on the Fimea website in early 2023.

More information on the national risk medicines project is now also available on the Fimea website. The website has information about the project, essential definitions and news related to the project, as well as contact details. Read more on the new pages of the project.

National Risk Medicines Classification